CBMG:NSD-Cellular Biomedicine Group, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.38B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Cellular Biomedicine Group, Inc (CBMG) Stock Analysis:
Based on the Cellular Biomedicine Group, Inc stock forecasts from 0 analysts, the average analyst target price for Cellular Biomedicine Group, Inc is not available over the next 12 months. Cellular Biomedicine Group, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cellular Biomedicine Group, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Cellular Biomedicine Group, Inc’s stock price was USD 0.00. Cellular Biomedicine Group, Inc’s stock price has changed by +0.00 % over the past week, +0.00 % over the past month and +0.00 % over the last year.

About

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune ce ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-9.12 (-2.94%)

USD149.41B 18.61 18.13
BNTX BioNTech SE

-0.99 (-0.30%)

USD85.30B 11.13 8.07
REGN Regeneron Pharmaceuticals Inc

+3.41 (+0.54%)

USD70.38B 10.09 8.03
VRTX Vertex Pharmaceuticals Incorpo..

-0.55 (-0.27%)

USD48.34B 24.59 14.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-6.11 (-1.74%)

USD33.10B N/A N/A
SGEN Seagen Inc

+0.42 (+0.27%)

USD29.26B 55.02 44.86
GMAB Genmab A/S

-0.54 (-1.42%)

USD25.19B 58.75 6.30
ALNY Alnylam Pharmaceuticals Inc

+2.92 (+1.62%)

USD21.98B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CBMG

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.26% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.26% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.36% N/A N/A N/A N/A
Risk Adjusted Return 42.79% N/A N/A N/A N/A
Market Capitalization 0.38B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 22.21 N/A N/A N/A N/A
Price / Cash Flow Ratio -9.70 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -129.91% N/A N/A N/A N/A
Return on Invested Capital -65.68% N/A N/A N/A N/A
Return on Assets -34.66% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.48 N/A N/A N/A N/A
Short Percent 3.22% N/A N/A N/A N/A
Beta 1.21 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.